glp-1 medication risks compounding pharmacies Overdose increase as demand for injectable weight-loss drugs on the rise, research finds Microdosing GLP-1: Understanding the Risks
Description
In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [89]
Increased Vision Impairment Reports Linked to Semaglutide: Analysis of FDA Adverse Event Data
Individuals with obesity and elevated blood pressure Weight loss achieved through GLP-1 therapy often correlates with blood pressure improvements
Consider: Will weight loss patients have to take these drugs forever
L., Richardson, K
